FAQ: What are predictive risk factors for disease severity in CD and UC?
Thank you to Johnson & Johnson for your support of this FAQ Video Module.In this FAQ video module, Erin Darguzas, NP, Gastroenterology Specialist at Northwestern Medicine, discusses the predictive ris...
13 Feb 20252min
FAQ: What lifestyle changes are essential for managing cirrhosis effectively?
In this video, Sherona Bau, NP, from the Pfleger Liver Institute at UCLA, discusses the essential lifestyle changes for effectively managing cirrhosis. Maintaining a healthy lifestyle is key to slowin...
12 Feb 20252min
Journal Club: Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results
Thank you to Johnson & Johnson for your support of this Journal Club Video Module.In this video, Jamie Brogan, NP, from Northwestern Medicine in Chicago, discusses the efficacy and safety of Guselkuma...
11 Feb 20254min
FAQ: How Can You Support a Shared Decision-Making Process With the Patient?
In this video, Allison Moser, a transplant hepatology nurse practitioner at Rush University Medical Center, discusses the key principles of shared decision-making and how healthcare providers can bett...
10 Feb 20252min
Medication Review: What is the efficacy of guselkumab in ulcerative colitis and Crohn's disease?
Thank you to Johnson & Johnson for your support of this Medication Review Video Module.In this comprehensive medication review, Peter Byrne, FNP, from South Denver Gastroenterology, discusses the effi...
6 Feb 20258min
FAQ: How can physicians better care for patients with cirrhosis?
Sherona Bau, NP, at Pfleger Liver Institute, discusses the importance of providing effective care for patients with cirrhosis, which requires a proactive and comprehensive approach from healthcare pro...
5 Feb 20252min
Medication Review: What is the safety profile of guselkumab in ulcerative colitis and Crohn's disease?
Thank you to Johnson & Johnson for your support of this Medication Review Video Module.In this medication review module, Peter Byrne, FNP at South Denver Gastroenterology, discusses the safety of guse...
4 Feb 20255min
Journal Club: Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
Thank you to Johnson & Johnson for your support of this Journal Club Video Module.In this Journal Club video module, Jamie Brogan, NP, from Northwestern, discusses findings from the Phase 2 GALAXI-1 S...
30 Jan 20253min
